Interaction of molecular alterations with immune response in melanoma.

about

Rho GTPase effectors and NAD metabolism in cancer immune suppression.Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.Cancer: Precision T-cell therapy targets tumours

P2860

Q45974765-BF3973FD-E9A8-4978-85C6-CBF695F10048 Q55632531-F0B5B5F2-8524-409A-9EDE-2C22818A0AC5 Q59093422-B0AFED46-3039-4C83-A0B2-E2689C997835

P2860

Interaction of molecular alterations with immune response in melanoma.

Item

http://www.wikidata.org/entity/Q39329609

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Interaction of molecular alterations with immune response in melanoma.

@en

Interaction of molecular alterations with immune response in melanoma.

@nl

type

Item

label

Interaction of molecular alterations with immune response in melanoma.

@en

Interaction of molecular alterations with immune response in melanoma.

@nl

prefLabel

Interaction of molecular alterations with immune response in melanoma.

@en

Interaction of molecular alterations with immune response in melanoma.

@nl

P1476

Interaction of molecular alterations with immune response in melanoma

@en

P2093

Alexandre Reuben

http://www.w3.org/2001/XMLSchema#string

Jennifer A Wargo

http://www.w3.org/2001/XMLSchema#string

Xue Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

A landscape of driver mutations in melanoma

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

P304

2130-2142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30681

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

S11

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Robert Sloane

Sangeetha Reddy

Vancheswaran Gopalakrishnan

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28543700

http://www.w3.org/2001/XMLSchema#string

P921

Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase

P932

6105277

http://www.w3.org/2001/XMLSchema#string

Interaction of molecular alterations with immune response in melanoma.

about

P2860

P2860

Interaction of molecular alterations with immune response in melanoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932